Search

Jean A Chmielewski

from Lafayette, IN
Age ~63
Get Report
Also known as:
Jean A Chimielewski, Jean A Lipton, Jean A Chmieleweski, Jea Chmielewski
Phone and address:
511 9Th St, Lafayette, IN 47901
(765) 429-5422
Related to:
Walter K LiptonJean P Lipton, 76Mark A Lipton, 65
Connected to:
Amber E Chmielewski, 37Ami C Chmielewski, 59Ana P Chmielewski, 62Brian D Chmielewski, 54Casey M Chmielecki, 41Charles Chmielewski, 66Christina Chmielewski, 55Christopher A Chmielewski, 41Colin D Chmielewski, 47Courtney Chmieleski, 30

Jean Chmielewski Phones & Addresses

  • 511 9Th St, Lafayette, IN 47901 (765) 429-5422
  • La Fayette, IN
  • Berkeley, CA
  • New York, NY
  • Richmond, CA

Work

Company: Purdue university Position: Distinguished professor

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Purdue University 2003 to 2005 Specialities: Philosophy

Industries

Higher Education

Professional Records

License Records

Jean M Chmielewski

License #:
041127232 - Expired
Issued Date:
Aug 23, 1968
Type:
Registered Professional Nurse

Resumes

Resumes

Jean Chmielewski Photo 1

Distinguished Professor

View page
Location:
Lafayette, IN
Industry:
Higher Education
Work:
Purdue University
Distinguished Professor
Education:
Purdue University 2003 - 2005
Doctorates, Doctor of Philosophy, Philosophy

Publications

Us Patents

Collagen Peptide Conjugates And Uses Therefor

View page
US Patent:
8575311, Nov 5, 2013
Filed:
May 15, 2009
Appl. No.:
12/992759
Inventors:
Jean A Chmielewski - Lafayette IN, US
Marcos M Pires - West Lafayette IN, US
David E Przybyla - Lafayette IN, US
Assignee:
Purdue Research Foundation - West Lafayette IN
International Classification:
C07K 14/00
US Classification:
530350
Abstract:
Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes, as drug delivery vehicles and in delivering populations of cells to a site of disease or injury.

Methods And Compositions For Reversing P-Glycoprotein Medicated Drug Resistance

View page
US Patent:
20100068786, Mar 18, 2010
Filed:
Sep 16, 2009
Appl. No.:
12/561014
Inventors:
Jean A. Chmielewski - Lafayette IN, US
Christine A. Hrycyna - Lafayette IN, US
Marcos M. Pires - West Lafayette IN, US
International Classification:
C12N 9/16
C07H 19/06
C07D 221/28
C07D 233/02
C07D 215/42
US Classification:
435196, 435325, 536 284, 536 2854, 546 74, 5483211, 564360
Abstract:
A method for inhibiting therapeutic drug resistance within a cell over-expressing a membrane protein is provided. The method comprises synthesizing a dimeric prodrug inhibitor of a monomeric therapeutic agent; administering the dimeric prodrug inhibitor to the membrane protein together with the monomeric therapeutic agent; and occupying at least one substrate binding site of the membrane protein with the synthesized dimeric prodrug to allow the monomeric therapeutic agent to accumulate within the cell. The dimeric prodrug inhibitor contains a crosslinking agent that is adapted to breakdown under reducing conditions within the cytosol of the cell to cause the dimeric prodrug to revert back to a form equivalent to the monomeric therapeutic agent.

Pharmaceutical Materials And Methods For Their Preparation And Use

View page
US Patent:
7001892, Feb 21, 2006
Filed:
Jun 12, 2000
Appl. No.:
10/018043
Inventors:
Jean A. Chmielewski - Lafayette IN, US
Bart E. Kahr - Seattle WA, US
Jerry Lewis - Carmel IN, US
Assignee:
Purdue Research Foundation - West Lafayette IN
International Classification:
A61K 31/7016
A61K 47/26
US Classification:
514 53, 53612313
Abstract:
Pharmaceutical compositions comprising crystals of a pharmaceutically-acceptable crystal lattice component, and an active pharmaceutical ingredient different from and included within the crystal lattice component in a growth-sector specific orientation. The crystals are prepared using components and methods which yield crystals having suitable purity and efficacy for use in administering the active pharmaceutical ingredients to a patient. The crystals are typically combined with adjuvants such as excipients, diluents or carriers, and are preferably formulated into tablets, capsules, suspensions, and other conventional forms containing predetermined amounts of the pharmaceuticals. Also provided are methods for preparing the crystals, and methods for storing and administering the active pharmaceutical ingredient either included within the crystals or upon reconstitution of the crystals to a solution.

Fluorescent Assay Systems For Real-Time Measurement Of Protein Ubiquitination And Uses Thereof

View page
US Patent:
20210396743, Dec 23, 2021
Filed:
Jun 18, 2021
Appl. No.:
17/351422
Inventors:
- West Lafayette IN, US
Kedar Puvar - West Lafayette IN, US
Aya M. Saleh - West Lafayette IN, US
Ryan William Curtis - Lafayette IN, US
Tamara Lea Kinzer-Ursem - West Lafayette IN, US
Jean Anne Chmielewski - Lafayette IN, US
Assignee:
Purdue Research Foundation - West Lafayette IN
International Classification:
G01N 33/544
G01N 21/64
G01N 33/68
Abstract:
A radical departure from the classical E1-E2-E3 three-enzyme mediated ubiquitination of eukaryotes, the bacterial enzymes of the SidE family of effectors utilize NAD to ligate ubiquitin onto target substrate proteins achieved via a two-step mechanism involving (1) ADP-ribosylation of ubiquitin followed by (2) phosphotransfer to a target serine residue. Using fluorescent NAD analogues as well as synthetic substrate mimics, a continuous assay system enabling real-time monitoring of both steps of this mechanism is disclosed herein. These assays are amenable to biochemical studies and high-throughput screening of inhibitors of these effectors, and enable the discovery and characterization of putative enzymes similar to the SidE family in other organisms. A kit of the assay system, for real-time monitoring protein ubiquitination and/or identifying an inhibitor for protein ubiquitination comprising a fluorescent NAD+ analogue and a synthetic substrate mimic, is also in the scope of this disclosure.

Dual-Action, Unnatural Proline-Rich Peptides As Antibiotic Agents And Methods Thereof

View page
US Patent:
20150314009, Nov 5, 2015
Filed:
May 1, 2015
Appl. No.:
14/702530
Inventors:
- West Lafayette IN, US
Jean Anne Chmielewski - Lafayette IN, US
International Classification:
A61K 47/48
A61K 49/00
A61K 31/7036
Abstract:
The present invention cationic amphiphilic polyproline helices (CAPHs) compounds having increased hydrophobicity and cellular internalization as antimicrobial agents. Antimicrobial compositions and methods of using the same are also provided.
Control profile
Jean A Chmielewski from Lafayette, IN, age ~63 Get Report